{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:55:36Z","timestamp":1791888936961,"version":"4.3.4"},"reference-count":40,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Context: Fibroblast growth factor (FGF)-23 is produced in bone, and circulating levels are markedly elevated in patients with end-stage kidney disease, but the relationship between plasma levels of FGF-23 and bone histology in dialysis patients with secondary hyperparathyroidism is unknown.<\/jats:p>\n                  <jats:p>Objective: The aim of the study was to evaluate the correlation between plasma levels of FGF-23 and bone histology in pediatric patients with end-stage kidney disease who display biochemical evidence of secondary hyperparathyroidism.<\/jats:p>\n                  <jats:p>Design: We performed a cross-sectional analysis of the relationship between plasma FGF-23 levels and bone histomorphometry.<\/jats:p>\n                  <jats:p>Setting: The study was conducted in a referral center.<\/jats:p>\n                  <jats:p>Study Participants: Participants consisted of forty-nine pediatric patients who were treated with maintenance peritoneal dialysis and who had serum PTH levels (1st generation Nichols assay) greater than 400 pg\/ml.<\/jats:p>\n                  <jats:p>Intervention: There were no interventions.<\/jats:p>\n                  <jats:p>Main Outcome Measure: Plasma FGF-23 levels and bone histomorphometry were measured.<\/jats:p>\n                  <jats:p>Results: No correlation existed between values of PTH and FGF-23. Bone formation rates correlated with PTH (r = 0.44; P &amp;lt; 0.01), but not with FGF-23. Higher FGF-23 concentrations were associated with decreased osteoid thickness (r = \u22120.49; P &amp;lt; 0.01) and shorter osteoid maturation time (r = \u22120.48; P &amp;lt; 0.01).<\/jats:p>\n                  <jats:p>Conclusions: High levels of FGF-23 are associated with improved indices of skeletal mineralization in dialyzed pediatric patients with high turnover renal osteodystrophy. Together with other biomarkers, FGF-23 measurements may indicate skeletal mineralization status in this patient population.<\/jats:p>","DOI":"10.1210\/jc.2008-0326","type":"journal-article","created":{"date-parts":[[2008,12,2]],"date-time":"2008-12-02T22:04:44Z","timestamp":1228255484000},"page":"511-517","source":"Crossref","is-referenced-by-count":133,"title":["Relationship between Plasma Fibroblast Growth Factor-23 Concentration and Bone Mineralization in Children with Renal Failure on Peritoneal Dialysis"],"prefix":"10.1210","volume":"94","author":[{"given":"Katherine","family":"Wesseling-Perry","sequence":"first","affiliation":[{"name":"Departments of Pediatrics (K.W.-P., R.C.P., B.G., I.B.S.), David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata C.","family":"Pereira","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics (K.W.-P., R.C.P., B.G., I.B.S.), David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hejing","family":"Wang","sequence":"additional","affiliation":[{"name":"Biomathematics (H.W., R.M.E.), David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Elashoff","sequence":"additional","affiliation":[{"name":"Biomathematics (H.W., R.M.E.), David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobha","family":"Sahney","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (S.S.), Loma Linda University, Loma Linda, California 92354"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gales","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics (K.W.-P., R.C.P., B.G., I.B.S.), David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Ju\u0308ppner","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (H.J.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02115"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro B.","family":"Salusky","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics (K.W.-P., R.C.P., B.G., I.B.S.), David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071613395812200_R1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ki.1994.31","article-title":"Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD\/CCPD.","volume":"45","author":"Salusky","year":"1994","journal-title":"Kidney Int"},{"key":"2020071613395812200_R2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/ki.1990.187","article-title":"Renal bone disease 1990: an unmet challenge for the nephrologist.","volume":"38","author":"Malluche","year":"1990","journal-title":"Kidney Int"},{"key":"2020071613395812200_R3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"2020071613395812200_R4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1046\/j.1523-1755.2003.00727.x","article-title":"Severe bone disease and low bone mineral density after juvenile renal failure.","volume":"63","author":"Groothoff","year":"2003","journal-title":"Kidney Int"},{"key":"2020071613395812200_R5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI200419081","article-title":"Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.","volume":"113","author":"Shimada","year":"2004","journal-title":"J Clin Invest"},{"key":"2020071613395812200_R6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.matbio.2004.09.007","article-title":"Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.","volume":"23","author":"Sitara","year":"2004","journal-title":"Matrix Biol"},{"key":"2020071613395812200_R7","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.bone.2007.01.017","article-title":"Mineralized tissue cells are a principal source of FGF23.","volume":"40","author":"Yoshiko","year":"2007","journal-title":"Bone"},{"key":"2020071613395812200_R8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","volume":"26","journal-title":"Nat Genet"},{"key":"2020071613395812200_R9","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","article-title":"Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.","volume":"64","author":"Larsson","year":"2003","journal-title":"Kidney Int"},{"key":"2020071613395812200_R10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/clinchem\/39.3.529","article-title":"Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer.","volume":"39","author":"Hollis","year":"1993","journal-title":"Clin Chem"},{"key":"2020071613395812200_R11","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1210\/jc.2005-2105","article-title":"Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.","volume":"91","author":"Imel","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613395812200_R12","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1046\/j.1523-1755.1998.00866.x","article-title":"Bone disease in children and adolescents undergoing successful renal transplantation.","volume":"53","author":"Sanchez","year":"1998","journal-title":"Kidney Int"},{"key":"2020071613395812200_R13","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3462-1","volume-title":"Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis","author":"Harrell","year":"2001"},{"key":"2020071613395812200_R14","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/ki.1993.64","article-title":"The spectrum of bone disease in end-stage renal failure\u2014an evolving disorder.","volume":"43","author":"Sherrard","year":"1993","journal-title":"Kidney Int"},{"key":"2020071613395812200_R15","volume-title":"The Robustreg procedure. SAS\/STAT 9.1 User\u2019s Guide. Chap 62","year":"2008"},{"key":"2020071613395812200_R16","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1681\/ASN.2004100885","article-title":"Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.","volume":"16","author":"Salusky","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2020071613395812200_R17","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/0272-6386(95)90453-0","article-title":"Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity.","volume":"26","author":"Wang","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"2020071613395812200_R18","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2001.00949.x","article-title":"Improved assessment of bone turnover by the PTH-(1-84)\/large C-PTH fragments ratio in ESRD patients.","volume":"60","author":"Monier-Faugere","year":"2001","journal-title":"Kidney Int"},{"key":"2020071613395812200_R19","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1523-1755.2005.00513.x","article-title":"Specific measurement of PTH (1\u201384) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry.","volume":"68","author":"Lehmann","year":"2005","journal-title":"Kidney Int"},{"key":"2020071613395812200_R20","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1046\/j.1523-1755.2003.00915.x","article-title":"Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis.","volume":"63","author":"Salusky","year":"2003","journal-title":"Kidney Int"},{"key":"2020071613395812200_R21","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1053\/ajkd.2002.34519","article-title":"PTH 1-84 and PTH \u201c7-84\u201d in the noninvasive diagnosis of renal bone disease.","volume":"40","author":"Coen","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2020071613395812200_R22","doi-asserted-by":"crossref","first-page":"c94","DOI":"10.1159\/000086347","article-title":"Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism","volume":"101","author":"Nishi","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"2020071613395812200_R23","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1523-1755.2005.00178.x","article-title":"Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.","volume":"67","author":"Kazama","year":"2005","journal-title":"Kidney Int"},{"key":"2020071613395812200_R24","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1523-1755.2005.00184.x","article-title":"Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.","volume":"67","author":"Nakanishi","year":"2005","journal-title":"Kidney Int"},{"key":"2020071613395812200_R25","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/sj.ki.5002622","article-title":"Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients.","volume":"73","author":"Urena","year":"2008","journal-title":"Kidney Int"},{"key":"2020071613395812200_R26","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0272-6386(95)90599-5","article-title":"Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis.","volume":"26","author":"Qi","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"2020071613395812200_R27","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1111\/j.1523-1755.2005.00603.x","article-title":"25-Hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy.","volume":"68","author":"Coen","year":"2005","journal-title":"Kidney Int"},{"key":"2020071613395812200_R28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1677\/joe.1.07059","article-title":"Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.","volume":"192","author":"Liu","year":"2007","journal-title":"J Endocrinol"},{"key":"2020071613395812200_R29","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bone.2006.04.012","article-title":"Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin.","volume":"39","author":"Rowe","year":"2006","journal-title":"Bone"},{"key":"2020071613395812200_R30","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med"},{"key":"2020071613395812200_R31","doi-asserted-by":"crossref","first-page":"36172","DOI":"10.1074\/jbc.M003622200","article-title":"Identification of osteoblast\/osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes.","volume":"275","author":"Petersen","year":"2000","journal-title":"J Biol Chem"},{"key":"2020071613395812200_R32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.bone.2003.10.005","article-title":"MEPE has the properties of an osteoblastic phosphatonin and minhibin.","volume":"34","author":"Rowe","year":"2004","journal-title":"Bone"},{"key":"2020071613395812200_R33","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ng1905","article-title":"Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism.","volume":"38","author":"Feng","year":"2006","journal-title":"Nat Genet"},{"key":"2020071613395812200_R34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0221-8747(81)90002-3","article-title":"Stimulation of cortical bone mineralization and remodeling by phosphate and 1,25-dihydroxyvitamin D in vitamin D-resistant rickets.","volume":"3","author":"Marie","year":"1981","journal-title":"Metab Bone Dis Relat Res"},{"key":"2020071613395812200_R35","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071613395812200_R36","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2020071613395812200_R37","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1523-1755.1998.00045.x","article-title":"Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration.","volume":"54","author":"Salusky","year":"1998","journal-title":"Kidney Int"},{"key":"2020071613395812200_R38","doi-asserted-by":"crossref","first-page":"E1636","DOI":"10.1152\/ajpendo.00396.2007","article-title":"Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice","volume":"293","author":"Liu","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2020071613395812200_R39","doi-asserted-by":"crossref","first-page":"E254","DOI":"10.1152\/ajpendo.90201.2008","article-title":"Pathogenic role of Fgf23 in Dmp1-null mice","volume":"295","author":"Liu","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2020071613395812200_R40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1258\/000456307781646102","article-title":"The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays.","volume":"44","author":"Durham","year":"2007","journal-title":"Ann Clin Biochem"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/2\/511\/9058867\/jcem0511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/2\/511\/9058867\/jcem0511.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T20:21:08Z","timestamp":1594930868000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/94\/2\/511\/2598232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,1]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2008-0326","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1147396.604571","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,1]]}}}